Bio-Rad Laboratories FY 2024: revenue $2.6B, down 4%; diluted EPS −$65.36

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

1. Revenue$2.6B−4% from $2.7B in FY 202310-K income statement, on EDGAR
2. Net income−$1.8BAgainst −$637.3M in FY 202310-K income statement, on EDGAR
3. Diluted EPS−$65.36Against −$21.82 in FY 202310-K income statement, on EDGAR
4. Cash and cash equivalents$488.1M+21% from $403.8M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
5. Cash from operations$455.2M+21% from $374.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables